Home / Market News / $RARE
benzinga Corporate Catalyst Impact 65/100 ● positive

Ultragenyx Settles DOJOLVI Patent Litigation With Navinta, Allowing Generic Entry Starting January 1, 2033; Or July 2033 With Pediatric Exclusivity; Similar Patent Litigation Against Other DOJOLVI Abbreviated New Drug Application Filers Related To DOJOLVI Remains Pending

Oct 19, 2026, 1:11 PM UTC · Primary ticker $RARE

Ultragenyx has settled patent litigation with Navinta, allowing generic DOJOLVI entry starting January 1, 2033, or July 1, 2033, with pediatric exclusivity. This provides clarity on future competition for DOJOLVI but the long lead time mitigates immediate negative impact, though it sets a definitive end to market exclusivity for this specific generic. Other similar litigations remain pending.

Ultragenyx (RARE) has reached a settlement with Navinta LLC regarding patent litigation for its drug DOJOLVI. This agreement grants Navinta a license to market a generic version of DOJOLVI starting January 1, 2033, potentially extended to July 1, 2033, if pediatric exclusivity is granted. This development is significant as it sets a definitive timeline for generic competition for DOJOLVI from one specific filer, providing some clarity for investors. While the long lead time (over six years) means no immediate revenue impact, it does establish a future erosion of market share for DOJOLVI. The short-term impact is neutral to slightly negative as the market has long anticipated generic challenges, but the long-term implications are negative for DOJOLVI's revenue stream post-2033. A key risk for traders is how the market will react to the pending litigations against other ANDA filers, as those outcomes could further accelerate or delay generic competition.

$RARE neutral Settled patent litigation, future generic entry date set
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.